



Terpenoids and hexenes from the leaves of *Crataegus pinnatifida*

Shao-Jiang Song^{a,*}, Ling-Zhi Li^a, Pin-Yi Gao^a, Ying Peng^{b,*}, Jing-Yu Yang^c, Chun-Fu Wu^c

^a School of Traditional Chinese Materia Medica, Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China

^b School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, PR China

^c School of Life Science and Biopharmaceutics, Shenyang Pharmaceutical University, Shenyang 110016, PR China

ARTICLE INFO

Article history:

Received 31 January 2011

Received in revised form 10 March 2011

Accepted 9 May 2011

Available online 14 May 2011

Keywords:

Crataegus pinnatifida

Sesquiterpene

Monoterpene

ABSTRACT

Crataegus pinnatifida have long been used in traditional Chinese medicine and European herbal medicine, and are widely consumed as food, in the form of juice, drink, jam and canned fruit. Four new compounds, a sesquiterpene and its glycoside (**1–2**), two monoterpene glycosides (**3–4**), together with eight known compounds (**5–12**), were isolated from the leaves of *C. pinnatifida*. Their structures were elucidated as (5Z)-6-[5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol (**1**), (5Z)-6-[5-(2-O-β-D-glucopyranosyl-propan-2-yl)-2-methyl tetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol (**2**), 5-ethenyl-2-[2-O-β-D-glucopyranosyl-(1'' → 6')-β-D-glucopyranosyl-propan-2-yl]-5-methyltetrahydrofuran-2-ol (**3**), 4-[4β-O-β-D-xylopyranosyl-(1'' → 6')-β-D-glucopyranosyl-2,6,6-trimethyl-1-cyclohexen-1-yl]-butan-2-one (**4**), (Z)-3-hexenyl O-β-D-glucopyranosyl-(1'' → 6')-β-D-glucopyranoside (**5**), (Z)-3-hexenyl O-β-D-xylopyranosyl-(1'' → 6')-β-D-glucopyranoside (**6**), (Z)-3-hexenyl O-β-D-rhamnopyranosyl-(1'' → 6')-β-D-glucopyranoside (**7**), (3R,5S,6S,7E,9S)-megastiman-7-ene-3,5,6,9-tetrol (**8**), (3R,5S,6S,7E,9S)-megastigman-7-ene-3,5,6,9-tetrol-9-O-β-D-glucopyranoside (**9**), (6S,7E,9R)-6,9-dihydroxy-4,7-megastigmadien-3-one 9-O-[β-D-xylopyranosyl-(1'' → 6')-β-D-glucopyranoside] (**10**), Linarionoside C (**11**), and (3S,9R)-3,9-dihydroxy-megastigman-5-ene 3-O-primeveroside (**12**), using a combination of mass spectroscopy, 1D and 2D NMR spectroscopy and chemical analysis. Cytotoxicity of the new compounds was assayed against selected human glioma (U87) cell lines.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Crataegus pinnatifida Bge var *major* N.E.Br. or *Crataegus pinnatifida* Bge., locally called Hawthorn, is widely distributed throughout the northern temperate regions of the world with approximately 280 species, primarily in East Asia, Europe and North America (Zhang, Ho, Huang, & Chen, 2002). Hawthorn fruits have long been used in traditional Chinese medicine and European herbal medicine, and are widely consumed as food, in the form of juice, drink, jam and canned fruit (Chang, Zuo, Chow, & Ho, 2006). The extract of hawthorn has been shown to have many health benefits including being cardiovascular protective, hypotensive, hypocholesterolaemic and lowers serum cholesterol (Yao, Ritchie, & Brown-Woodman, 2008; Zhang et al., 2001, 2002). Pharmacological and toxicological studies have demonstrated that consumption of hawthorn fruits is associated with long-term medicinal benefits to cardiovascular function with little side effect (Ammon & Handel, 1981a, 1981b, 1981c). Hawthorn fruits and leaves have a curative

effect on blood vessels of the heart which have been extensively reported (Frishman, Beravol, & Carosella, 2009; Frishman, Sinatra, & Moizuddin, 2004; Long, Carey, Crofoot, Proteau, & Filtz, 2006; Pittler, Schmidt, & Ernst, 2003). Previous studies on the chemical constituents of hawthorn led to the isolation of a series of diverse compounds, including flavonoids, terpenoids and organic acids. So far, more than 170 compounds have been isolated from *Crataegus* (Chen & Song, 2005; Dauguet, Bert, Dolley, Bekaert, & Lewin, 1993; Gao et al., 2010; Nikolov, Seligmann, Wagner, Horowitz, & Gentili, 1982; Zhang & Xu, 2001). In the present study, according to the pharmacokinetic data available, it appears that one of the potentially most active components of hawthorn, quercetin, is poorly bioavailable both *in vivo* and *in vitro*. However, quercetin is only one of many components of the hawthorn extract. The extent to which any of these other components might be available to the embryo is unknown (Yao et al., 2008). In order to evaluate the health protection value of hawthorn, the leaves of hawthorn was subjected to phytochemical investigation resulting in the isolation of a novel sesquiterpene and its glycoside (**1–2**), two novel monoterpene glycosides (**3–4**), together with eight known compounds (**5–12**). Their chemical structures (Fig. 1) were elucidated by their physicochemical properties and spectral data, such as 1D, 2D NMR and HRESI-MS.

* Corresponding authors. Tel.: +86 24 23986510 (S.-J. Song), +86 24 23986361 (Y. Peng).

E-mail addresses: songsj99@gmail.com, songsj99@163.com (S.-J. Song), ying-peng1999@yahoo.com.cn (Y. Peng).




Fig. 1. The structures of compounds 1–12.

2. Materials and methods

2.1. General methods

Optical rotations were measured with a Perkin–Elmer 241MC polarimeter. Silica gel (200–300 mesh, Qingdao Marine Chemical Co., China); Sephadex LH-20 (25–100 μ m, Greenherbs Science and Technology Development Co., Ltd., China); MCI gel (CHP20P, 75–150 μ m, Mitsubishi Chemical Corporation, Japan) and reversed-phase C_{18} silica gel (60–80 μ m, Merck, Germany) were used for column chromatography and silica gel GF254 (Qingdao Marine Chemical Co., China) for TLC. Solvents were of industrial purity and distilled prior to use.

2.2. Plant material

The leaves (5 kg) of *C. pinnatifida* were collected from Liaoning province, China in June 2007, and authenticated by Prof. Qi-Shi Sun, Department of Pharmacognosy, Shenyang Pharmaceutical University. A voucher specimen is kept in the Nature Products Laboratory of Shenyang Pharmaceutical University, Shenyang, China.

2.3. Extraction and isolation

Air-dried leaves (5 kg) of *C. pinnatifida* were extracted with 70% ethanol by reflux (95 $^{\circ}$ C, 2 h) three times. The ethanol extract was concentrated *in vacuo* to yield a brownish-dark crude extract (492 g), which was subjected to the macroporous resin (ethanol/water 0:100 \rightarrow 95:5) to yield 4 main fractions: Frs. A–D according to chemical monitoring by TLC. Fr. C (288 g) was further separated by CC (SiO_2 ; $CHCl_3$ /MeOH 100:1 \rightarrow 2:1) to provide 6 fractions (Frs. D1–D6), among which Fr. D2 (18 g) was purified by CC (SiO_2 ; $CHCl_3$ /MeOH 30:1), sequentially by CC (Sephadex LH-20; MeOH)

to yield compounds **1** (12 mg) and **5** (36 mg). Frs. D3 (20 g), D4 (35 g) and D5 (40 g) were applied to a column of MCI gel (methanol/water 0:100 \rightarrow 100:0), respectively, to collect major fractions. After removal of a large amount of water-soluble components, the major fractions of Frs. D3 were then combined on the basis of TLC analysis, and finally performed by reversed-phase C_{18} silica gel using MeOH/ H_2O with a gradient solvent system of (30:70 \rightarrow 90:10) and HPLC to obtain compounds **2** (16 mg), **6** (13 mg), **10** (22 mg), and **12** (17 mg). In the same way, compounds **3** (11 mg), **4** (38 mg), **7** (18 mg) were isolated from Frs. D4, and compounds **8** (27 mg), **9** (46 mg), **11** (15 mg) from Frs. D5.

2.4. Mass spectrometry

The HRESI-TOF-MS was obtained on a MicroTOF spectrometer (Bruker Daltonics, CA).

2.5. NMR spectroscopy

1H , ^{13}C NMR and 2D NMR data, including HSQC, HMBC, and NOESY, were measured on a Bruker ARX-600 spectrometer (298 K) instrument (Bruker Corporation, Bremen, Germany) operating at 600 MHz for 1H and 150 MHz for ^{13}C . The chemical shifts (δ) are reported in ppm down-field from tetramethylsilane (TMS) using TMS or the solvent signal as the standard in chloroform- d_1 or dimethyl sulfoxide- d_6 (DMSO- d_6).

2.6. Cytotoxic assay

Cytotoxic activities were performed according to the MTT method reported by Hussain, Nouri, and Oliver (1993). Tested-compounds were dissolved in DMSO and the final concentration of DMSO in the culture medium was controlled at less than 0.1%

(v/v). Cultivated human glioma (U87) cells were seeded in a 96-well plate with 1×10^4 cells/well. The plate was incubated with the tested compounds for 48 h, the MTT solution (2.5 mg/ml in PBS) was then added (10 μ l/well) and the plates were incubated for an additional 4 h at 37 °C. The produced formazan crystals were dissolved in 100 μ l of DMSO and the optical density of the solution was measured at 492 nm using a microplate reader (Synergy HT (Biotek)). The percentage of cytotoxic activity was determined by comparison with the control (DMSO).

The cytotoxicity of samples on tumour cells were expressed as IC₅₀ values (the drug concentration reducing the absorbance by 50% in treated cells, with respect to untreated cells), which were calculated by the LOGIT method.

3. Results and discussion

3.1. Phytochemical investigation

Compound **1** was obtained as a colourless oil. $[\alpha]_D^{20} = -12.0$ ($c = 0.14$, methanol). The molecular formula was established as C₁₅H₂₆O₃ by HRESI-MS, which showed a sodium adduct ion peak $[M+Na]^+$ at m/z 277.1776 (calculated 277.1774). ¹³C NMR spectrum of **1** displayed 15 carbon signals assigned to four methyls, four methylenes, four methines and three quaternary carbons (Table 1). Two olefin signals (δ_C 144.7, 139.5, 122.1 and 111.9) and four carbons bearing oxygen (δ_C 85.4, 82.6, 72.6 and 71.1) were evident. Furthermore, ¹H NMR spectrum of **1** showed the signals of terminal olefin signals at δ_H 5.19 (1H, $J = 17.1$, 1.8 Hz), 5.04 (1H, $J = 10.8$, 1.8 Hz) and 5.91 (1H, $J = 17.1$, 10.8 Hz), a *cis*-olefin signals at δ_H 5.54 (1H, $J = 7.2$, 3.9 Hz) and 5.53 (1H, $J = 7.2$ Hz), a carbon signal bearing oxygen at δ_H 3.76 (1H, $J = 6.6$ Hz) and four methyl

groups attached to the quaternary carbon at δ_H 1.26 (3H, s), 1.31 (3H, s), 1.21 (3H, s) and 1.12 (3H, s).

Analysis of the ¹H, ¹³C NMR and HSQC data helped us to allot H- to their bonded C-atoms, and further demonstration of the planar structure of **1** (Fig. 2) was obtained from the HMBC experiment. In the HMBC spectrum, the key correlations of a methylene unit with a terminal olefin group and a *cis*-olefin group, δ_C 144.7 (C-2)/H-1a, H-1b, H-4a, H-4b, H-15; 72.6 (C-3)/H-1a, H-1b, H-4a, H-4b, H-15; δ_C 45.1 (C-4)/H-2, H-5, H-6, H-15; δ_C 122.1 (C-5)/H-4a, H-4b, H-6; and δ_C 139.5 (C-6)/H-4a, H-4b, H-5, suggested the presence of Part 1 (Fig. 2). Furthermore, the key correlations of two methylene units with three carbons bearing oxygen and a *cis*-olefin groups, δ_C 139.5 (C-6)/H-5, H-8a, H-8b, H-14; δ_C 82.6 (C-7)/H-5, H-6, H-8a, H-8b, H-9a, H-9b, H-14; δ_C 37.8 (C-8)/H-9a, H-9b, H-14; δ_C 26.3 (C-9)/H-8a, H-8b, H-10; δ_C 85.4 (C-10)/H-8a, H-8b, H-9a, H-9b, H-12, H-13; and 71.1 (C-11)/H-9a, H-9b, H-10, H-12, H-13, indicated that two iso-pentenyl units were connected as Part 2 (Fig. 2). Unambiguously, C-5 and C-6 were allocated to the linkage site of Part 1 and Part 2. The stereochemistry of H-5 and H-6 was completely established by the coupling constants δ_H 5.54 (1H, $m, J = 7.2$, 3.9 Hz, H-5) and 5.53 (1H, $m, J = 7.2$ Hz, H-6) (Meng, Wu, & Zhao, 2010). Hence, the structure of compound **1** is deduced as (5Z)-6-[5-(2-hydroxypropan-2-yl)-2-methyl tetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol (**1**), a novel sesquiterpene named shanyegenin B.

Compound **2** was obtained as a colourless oil. $[\alpha]_D^{20} = -4.0$ ($c = 0.25$, methanol). The molecular formula was established as C₂₁H₃₆O₈ by HRESI-MS, which showed a sodium adduct ion peak $[M+Na]^+$ at m/z 439.2307 (calculated 439.2302). The ¹H and ¹³C NMR spectral data of **2** were very similar to those of **1** (Tables 1 and 2), except for the presence of one more glucopyranosyl which was determined by ¹H, ¹³C NMR and ESI-MS. Furthermore, the H-1'

Table 1
¹H NMR data for **1–4**.

No.	1 ^a	2 ^a	No.	3 ^a	No.	4 ^a
1a	5.19 dd (17.1, 1.8)	5.10 dd (17.1, 1.8)	1a	5.16 dd (17.1, 1.5)	1	
1b	5.04 dd (10.8, 1.8)	4.91 dd (10.8, 1.8)	1b	4.94 dd (10.5, 1.5)	2a	1.35 dd (12.3, 12.0)
2	5.91 dd (17.1, 10.8)	5.84 dd (17.1, 10.8)	2	5.91 dd (17.1, 10.5)	2b	1.73 brd (10.2)
3			3		3	3.90 brd (10.2)
4a	2.20 m	2.10 brd (3.9)	4a	1.87 m	4a	1.87 m
4b	2.21 m	2.10 d (3.9)	4b	2.03 m	4b	2.25 m
5	5.57 m	5.54 dd (7.2, 3.9)	5a	1.74 m	5	
6	5.58 m	5.53 d (7.2)	5b	1.83 m	6	
7			6		7a	2.06 m
8a	1.69 m	1.67 m	7		7b	2.15 m
8b	1.89 m	1.67 m	8	1.39 s	8a	2.44 m
9a	1.82 m	1.81 m	9	1.30 s	8b	2.44 m
9b	1.82 m	1.91 m	10	1.16 s	9	
10	3.86 t (6.6)	3.86 t (6.6)			10	2.07 s
11					11	0.98 s
12	1.26 s	1.09 s			12	0.98 s
13	1.31 s	1.16 s			13	1.54 s
14	1.21 s	1.16 s				
15	1.12 s	1.07 s				
1'		4.35 d (7.8)	1'	4.48 d (7.2)	1'	4.24 d (8.1)
2'		2.84 t (7.8)	2'	3.38 m	2'	2.98 m
3'		3.10 t (7.8)	3'	3.66 brd (8.4)	3'	3.54 m
4'		3.00 m	4'	3.14 m	4'	3.68 m
5'		3.02 m	5'	3.41 m	5'	3.69 m
6'a		3.35 brd (10.8)	6'a	2.95 m	6'a	3.05 m
6'b		3.62 brd (10.8)	6'b	3.65 m	6'b	3.05 m
1''			1''	4.14 d (7.5)	1''	4.20 d (7.5)
2''			2''	3.52 m	2''	3.28 m
3''			3''	3.06 m	3''	3.30 m
4''			4''	3.04 m	4''	3.31 m
5''			5''	3.41 m	5''a	3.15 m
6''a			6''a	3.05 brd (10.2)	5''b	3.87 m
6''b			6''b	4.03 brd (10.2)		

^a Recorded at 600 MHz.


Fig. 2. Key HMBC correlations (C → H) of **1**.

Table 2
¹³C NMR data for **1–12**.

No.	1 ^a	2 ^a	3 ^a	4 ^a	5 ^a	6 ^a	7 ^a	8 ^a	9 ^a	10 ^a	11 ^a	12 ^a
1	111.9	111.3	111.1	37.3	69.2	69.0	68.8	41.2	41.3	36.5	38.1	37.8
2	144.7	146.4	144.6	45.9	28.4	28.3	28.0	46.7	46.6	48.0	47.2	46.5
3	72.6	71.9	84.9	70.0	126.1	126.0	125.7	63.6	63.5	199.5	74.4	71.0
4	45.5	45.5	35.5	38.0	133.7	133.7	133.4	46.2	46.0	125.7	39.5	39.6
5	122.1	123.0	33.7	124.3	21.0	20.9	20.6	76.7	77.0	163.0	124.5	123.7
6	139.5	139.4	107.9	136.2	15.0	15.0	14.6	77.8	77.5	55.3	138.2	137.6
7	82.6	82.5	78.0	21.4				129.9	133.5	128.1	24.5	24.6
8	37.8	38.1	28.4	43.6				135.7	132.6	137.4	39.0	40.1
9	26.3	26.7	24.9	208.2				67.8	76.6	76.5	77.6	66.8
10	85.4	83.9	22.6	29.7				25.5	22.3	21.5	20.2	23.9
11	71.1	78.3		28.4				28.0	28.0	27.6	29.1	28.8
12	27.1	27.3		29.4				26.6	26.6	28.3	30.4	30.1
13	27.1	26.4		19.5				27.8	27.9	23.8	20.4	20.0
14	27.1	24.0										
15	24.1	22.2										
1'		97.6	93.9	103.9	103.5	103.5	103.3		101.7	101.6	101.6	101.1
2'		74.0	72.2	73.4	74.4	74.1	73.8		74.5	74.4	74.4	73.9
3'		77.5	73.9	76.7	77.7	77.4	77.1		77.7	77.5	77.6	77.1
4'		70.6	70.4	69.6	70.9	70.4	70.7		71.0	70.6	71.1	70.5
5'		77.0	77.3	75.8	76.7	76.6	75.8		77.7	75.3	77.6	76.1
6'		61.6	69.0	68.3	69.1	69.1	68.8		61.9	69.0	62.1	68.8
1''			103.6	100.5	104.1	100.7	101.3			104.8	101.6	104.4
2''			73.0	73.4	74.2	74.1	71.1			74.2	74.4	73.9
3''			77.3	76.6	77.6	77.4	71.0			77.5	77.6	77.0
4''			71.0	70.3	70.9	70.4	72.4			70.4	71.0	70.1
5''			77.3	65.7	77.7	66.4	67.8			66.5	77.6	66.1
6''			61.4		61.9		18.4				62.1	

^a Recorded at 150 MHz.

at δ_{H} 4.35 showed correlation with the carbon signal at δ_{C} 78.3 (C-11), indicating the occurrence of a glucopyranosyl at C-11 (Fig. 3).

The relative stereochemistry of **2** was completely established by the NOESY spectrum (Fig. 3), the significant NOESY correlation signals were observed at 12, 13-CH₃/H-1' and 10-CH₃/12, 13, 14-CH₃, indicating that the H-10 and 14-CH₃ were all on the same side of furan-ring (Meng et al., 2010). From the anomeric carbon (δ_{C} 97.6) and the anomeric proton [δ_{H} 4.35 (1H, d, J = 7.8 Hz)] and other characteristic NMR resonances, the sugar unit was identified as β -glucopyranose, which was further confirmed by strong NOE signals between H-1_{glc} and H-3_{glc}, H-5_{glc} (Agrawal, 1992). Therefore, compound **2** was concluded to be (5Z)-6-[5-(2-O- β -D-glucopyranosyl-propan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol (**2**), and given the trivial name shanyeside B.

Compound **3** was obtained as a colourless oil. $[\alpha]_{\text{D}}^{20}$ = +13.6 (c = 0.18, methanol). The molecular formula was established as C₂₂H₃₆O₁₂ by HRESI-MS, which showed a sodium adduct ion peak $[\text{M}+\text{Na}]^+$ at m/z 515.2093 (calculated 515.2099). The ¹H NMR spectrum (Table 1), showed the proton signals of a terminal olefin

group at δ_{H} 5.16 (1H, J = 17.1, 1.5 Hz), 4.94 (1H, J = 10.5, 1.5 Hz) and 5.91 (1H, J = 17.1, 10.5 Hz), as well as three methyl groups attached to the quaternary carbon at δ_{H} 1.39 (3H, s), 1.30 (3H, s) and 1.16 (3H, s). The ¹³C NMR spectrum exhibited three methyls (δ_{C} 28.4, 24.9, 22.6), three methylenes (δ_{C} 111.1, 35.5, 33.7), one methine (δ_{C} 144.6), and three quaternary carbons (δ_{C} 107.9, 84.9, 78.0), which suggested that **3** has a monoterpene skeleton. Further demonstrating the planar skeleton structure of **3** was obtained from the HMBC experiment (Fig. 3). The HMBC spectrum exhibited correlations from δ_{C} 84.9 (C-3) to H-1a, H-1b, H-4a, H-4b, H-10; δ_{C} 35.5 (C-4) to H-5a, H-5b, H-10; δ_{C} 33.7 (C-5) to H-4a, H-4b; δ_{C} 107.9 (C-6) to H-5a, H-5b, H-8, H-9, H-2'; and δ_{C} 78.0 (C-7) to H-5a, H-5b, H-8, H-9, H-1', indicating the presence of monoterpene skeleton. In the sugar part, two anomeric proton signals at δ_{H} 4.48 (1H, J = 7.2 Hz), 4.14 (1H, J = 7.5 Hz) and the ¹³C NMR signals of sugars showed the existence of two glucopyranosyl moieties (Tables 1 and 2). ³J_{C-H} correlations of genin and sugars were observed not only between the anomeric proton at δ_{H} 4.48 and the carbon at δ_{C} 78.0, but also between δ_{H} 3.38 and δ_{C} 107.9, which indicated the double linkage. The high-field shifting of δ_{C} 93.9 (C-1') and 73.9 (C-3') compared with usual values could




Fig. 3. Key HMBC correlations (C → H) of **2**, **3** and **4**. Key NOESY correlations (H → H) of **2** and **3**.

readily be explained by β -effects due to etherification of position 1' and 2' at the same time (Chang & Case, 2005). Except (β -effects), the C-2' signal was also affected by steric hindrance and finally shifted to higher-field. The glucosyl moiety was identified by acid hydrolysis of **3** with comparison to an authentic sample.

Finally, the relative stereochemistry of **3** was completely established by the NOESY spectrum and coupling constants. Significant NOESY correlation signals were observed at 9, 10-CH₃/H-4, 5 and 9-CH₃/10-CH₃ indicating, that the 9-CH₃ and 10-CH₃ were all on the same side of furan-ring (Fig. 3). Additionally, the β -stereochemistry of anomeric carbons were determined by the coupling constants ($J = 7.2$ and $J = 7.5$) of the anomeric protons (Agrawal, 1992). Therefore, the structure of **3** was identified as 5-ethenyl-2-[2-O- β -D-glucopyranosyl-(1''86')- β -D-glucopyranosyl-propan-2-yl]-5-methyltetrahydrofuran-2-ol, and given the trivial name shanyeside C.

Compound **4** was also obtained as a colourless oil. $[\alpha]_D^{20} = -14.0$ ($c = 0.21$, methanol). The ESI-MS showed a sodium adduct ion peak at m/z 527 $[M+Na]^+$ and a quasimolecular ion 503 $[M-H]^-$, indicating a molecular weight of 504. According to the HRESI-MS, 1H and ^{13}C NMR spectroscopic data, the molecular formula of **4** was determined to be $C_{24}H_{40}O_{11}$, $[M+Na]^+$ at m/z 527.2465 (calculated 527.2463). The 1H NMR spectrum (Table 1), showed the presence of four methyl groups attached to the quaternary carbon at δ_H 2.07 (3H, s), 1.54 (3H, s), 0.98 (3H, s) and 1.01 (3H, s). The ^{13}C NMR spectrum exhibited four methyls (δ_C 29.7, 29.4, 28.4, 19.5), four methylenes (δ_C 24.0, 40.4, 46.0, 47.8), one methine (δ_C 70.0), and four quaternary carbons (δ_C 37.3, 124.3, 136.2, 208.2), in addition to the sugar part. Further analysis of 2D NMR spectra of **4** indicated that this compound was an ionone derivative (Miyase, Ueno, Takizawa, Kobayashi, & Oguchi, 1988). Two sugar linkages of the β -form were indicated by the coupling constants of the anomeric proton signals at δ_H 4.24 (1H, d, $J = 8.1$ Hz) and 4.20 (1H, d, $J = 7.5$ Hz) in the 1H NMR data. In addition, the ^{13}C NMR signals showed the existence of glucopyranosyl and xylopyranosyl moieties as shown in Table 1. These observations were also confirmed by acid hydrolysis and comparison with an authentic sample. The down-field shift of the glucose C-6' signal (δ_C 68.3) indicated that xylopyranose and glucopyranose were linked through a 1 → 6

glycosidic bond. The glycosidic site was established unambiguously by a HMBC experiment in which long-range correlation between H-1' (δ_H 4.24) and C-3 (δ_C 70.0) was observed (Fig. 3). The relative configuration at C-3 was determined to be β -stereochemistry by the coupling constant ($J_{3-4\beta} = 10.1$ and $J_{3-2\beta} = 12.0$) (Chang & Case, 2005). Consequently, the structure of compound **4** was established as 4-[4 β -O- β -D-xylopyranosyl-(1'' → 6')- β -D-glucopyranosyl-2,6,6-trimethyl-1-cyclohexen-1-yl]-butan-2-one, and given the trivial name shanyeside D.

The known compounds were identified by comparing their physical and spectroscopic data with values reported in the literature. They are (Z)-3-hexenyl O- β -D-glucopyranosyl-(1'' → 6')- β -D-glucopyranoside (**5**) (Noiarsa et al., 2007), (Z)-3-hexenyl O- β -D-xylopyranosyl-(1'' → 6')- β -D-glucopyranoside (**6**) (Kishida, Fujii, Ida, & Akita, 2005), (Z)-3-hexenyl O- β -D-rhamnopyranosyl-(1'' → 6')- β -D-glucopyranoside (**7**) (Kishida et al., 2005), (3R,5S,6S,7E,9S)-megastiman-7-ene-3,5,6,9-tetrol (**8**) (Tung et al., 2009), (3R,5S,6S,7E,9S)-megastigman-7-ene-3,5,6,9-tetrol 9-O- β -D-glucopyranoside (**9**) (Yamamoto et al., 2008), (6S,7E,9R)-6,9-dihydroxy-4,7-megastigmadien-3-one 9-O- $[\beta$ -D-xylopyranosyl-(1'' → 6')- β -D-glucopyranoside] (**10**) (Matsuda, Isawa, & Kikuchi, 1997), Linarionoside C (**11**) (Otsuka, 1994), and (3S,9R)-3,9-dihydroxy-megastigman-5-ene 3-O-primeveroside (**12**) (Otsuka & Tamaki, 2002).

3.2. Characteristic data of compounds

(5Z)-6-[5-(2-Hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol (**1**): colourless oil; $[\alpha]_D^{20} = -12.0$ ($c = 0.14$, methanol); HRESI-MS m/z : 277.1776 (calcd. for $C_{15}H_{26}O_3 + Na^+$, 277.1774); see Table 1 for 1H NMR and see Table 2 for ^{13}C NMR.

(5Z)-6-[5-(2-O- β -D-glucopyranosyl-propan-2-yl)-2-methyltetrahydrofuran-2-yl]-3-methylhexa-1,5-dien-3-ol (**2**): colourless oil; $[\alpha]_D^{20} = -4.0$ ($c = 0.25$, methanol); HRESI-MS m/z : 439.2307 (calcd. for $C_{21}H_{36}O_8 + Na^+$, calculated 439.2302); see Table 1 for 1H NMR and see Table 2 for ^{13}C NMR.

5-Ethenyl-2-[2-O- β -D-glucopyranosyl-(1'' → 6')- β -D-glucopyranosyl-propan-2-yl]-5-methyltetrahydrofuran-2-ol(**3**): colourless

Table 3Cytotoxicity of compounds **1–4** isolated from the leaves of *C. pinnatifida*.

Compound	Control	0.1 μ M	1 μ M	10 μ M	100 μ M	IC ₅₀ (μ M)
1	0.00 \pm 0.60	3.45 \pm 0.64**	4.10 \pm 0.70**	5.17 \pm 1.22***	1.96 \pm 0.53	>100
2	0.00 \pm 0.96	8.52 \pm 1.30***	1.88 \pm 0.18*	5.78 \pm 1.04**	3.20 \pm 0.52*	>100
3	0.00 \pm 0.63	2.57 \pm 1.05*	2.14 \pm 0.56	2.40 \pm 0.49	3.19 \pm 0.64*	>100
4	0.00 \pm 0.73	1.62 \pm 0.96	−0.59 \pm 0.67	1.18 \pm 0.95	0.28 \pm 0.75	>100
		1 μ M	10 μ M	100 μ M	1000 μ M	
5-Fu	0.00 \pm 0.74	−6.25 \pm 0.54***	10.79 \pm 0.76***	30.41 \pm 0.53***	52.29 \pm 0.35***	727.14

* $P < 0.05$ vs control.** $P < 0.01$ vs control.*** $P < 0.001$ vs control.

oil; $[\alpha]_D^{20} = +13.6$ ($c = 0.18$, methanol); HRESI-MS m/z : 515.2093 (calculated for $C_{22}H_{36}O_{12} + Na^+$, 515.2099); see Table 1 for 1H NMR and see Table 2 for ^{13}C NMR.

4-[4- β -O- β -D-Xylopyranosyl-(1'' \rightarrow 6')- β -D-glucopyranosyl-2,6,6-trimethyl-1-cyclohexen-1-yl]-butan-2-one (**4**): colourless oil; $[\alpha]_D^{20} = -14.0$ ($c = 0.21$, methanol); HRESI-MS m/z : 527.2465 (calculated for $C_{24}H_{40}O_{11} + Na^+$, 527.2463); see Table 1 for 1H NMR and see Table 2 for ^{13}C NMR.

(Z)-3-Hexenyl O- β -D-glucopyranosyl-(1'' \rightarrow 6')- β -D-glucopyranoside (**5**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.92 (3H, t, $J = 7.5$ Hz, H-6), 2.03 (2H, m, $J = 6.9$ Hz, H-5), 2.27 (2H, q, $J = 6.9$ Hz, H-2), 3.49 (1H, m, H-1), 4.13 (1H, d, $J = 7.8$ Hz, H-1'), 4.25 (1H, d, $J = 7.8$ Hz, H-1''), 5.36 (2H, m, $J = 10.8$ Hz, H-3, 4).

(Z)-3-Hexenyl O- β -D-xylopyranosyl-(1'' \rightarrow 6')- β -D-glucopyranoside (**6**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.92 (3H, t, $J = 7.5$ Hz, H-6), 2.03 (2H, m, $J = 6.9$ Hz, H-5), 2.27 (2H, q, $J = 6.9$ Hz, H-2), 3.42 (1H, m, H-1), 4.14 (1H, d, $J = 7.8$ Hz, H-1'), 4.17 (1H, d, $J = 7.5$ Hz, H-1''), 5.39 (2H, m, $J = 10.8$ Hz, H-3, 4).

(Z)-3-Hexenyl O- β -D-rhamnopyranosyl-(1'' \rightarrow 6')- β -D-glucopyranoside (**7**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.92 (3H, t, $J = 7.5$ Hz, H-6), 1.12 (3H, d, $J = 6.0$ Hz, H-6''), 2.01 (2H, m, $J = 6.9$ Hz, H-5), 2.27 (2H, q, $J = 6.6$ Hz, H-2), 3.41 (1H, m, H-1), 4.12 (1H, d, $J = 7.8$ Hz, H-1'), 4.57 (1H, d, $J = 1.8$ Hz, H-1''), 5.37 (2H, m, $J = 10.8$ Hz, H-3, 4).

(3R,5S,6S,7E,9S)-Megastiman-7-ene-3,5,6,9-tetrol (**8**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.71 (3H, s, H-11), 0.99 (3H, s, H-13), 1.08 (3H, s, H-13), 1.12 (3H, s, $J = 6.3$ Hz, H-10), 1.25 (1H, dd, $J = 12.3$, 3.2 Hz, H-2 eq), 1.48 (1H, m, $J = 12$ Hz, H-2ax), 1.56 (2H, m, H-4), 3.85 (1H, m, H-3), 4.52 (1H, d, $J = 7.5$ Hz, H-9), 5.66 (1H, dd, $J = 12.9$, 6.0 Hz, H-8), 5.91 (1H, d, $J = 12.9$ Hz, H-7).

(3R,5S,6S,7E,9S)-Megastigman-7-ene-3,5,6,9-tetrol 9-O- β -D-glucopyranoside (**9**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.72 (3H, s, H-11), 1.00 (3H, s, H-13), 1.05 (3H, s, H-13), 1.20 (3H, s, $J = 6.3$ Hz, H-10), 1.25 (1H, dd, $J = 12.3$, 3.2 Hz, H-2 eq), 1.48 (1H, m, $J = 12$ Hz, H-2ax), 1.56 (2H, m, H-4), 3.85 (1H, m, H-3), 4.14 (1H, d, $J = 7.8$ Hz, H-1'), 4.32 (1H, d, $J = 7.5$ Hz, H-9), 5.72 (1H, dd, $J = 12.9$, 6.0 Hz, H-8), 5.97 (1H, d, $J = 12.9$ Hz, H-7).

(6S,7E,9R)-6,9-Dihydroxy-4,7-megastigmadien-3-one 9-O- $[\beta$ -D-xylopyranosyl-(1'' \rightarrow 6')- β -D-glucopyranoside] (**10**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.90 (3H, s, H-12), 0.94 (3H, s, H-11), 1.18 (3H, s, $J = 6.3$ Hz, H-10), 1.84 (3H, s, H-13), 1.94 (1H, d, $J = 16.5$ Hz, H-2 eq), 2.35 (1H, d, $J = 16.5$ Hz, H-2ax), 2.63 (H, d, $J = 8.7$ Hz, H-6), 3.51 (1H, m, H-6'a), 3.68 (1H, m, H-5''b), 3.87 (1H, m, H-6'b), 4.18 (1H, d, $J = 7.8$ Hz, H-1'), 4.19 (1H, d, $J = 7.8$ Hz, H-1''), 4.28 (1H, d, $J = 6.0$ Hz, H-9), 5.56 (1H, dd, $J = 15.9$, 9.0 Hz, H-7), 5.68 (1H, dd, $J = 15.9$, 6.0 Hz, H-8), 5.79 (1H, s, H-4).

Linarionoside C (**11**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 1.03 (3H, s, H-11), 1.06 (3H, s, H-12), 1.10 (3H, s, $J = 6.3$ Hz, H-10), 1.57 (3H, s, H-13), 1.23–1.39 (3H, m, H-2, H-8), 1.72 (1H, m, H-4ax), 1.88 (2H, m, H-7), 2.25 (1H, m, H-4 eq), 3.43–3.67 (4H, m, H-6', H-6''), 3.75

(H, m, H-9), 3.92 (H, m, H-3), 4.17 (1H, d, $J = 7.5$ Hz, H-1'), 4.26 (1H, d, $J = 7.8$ Hz, H-1'').

(3S,9R)-3,9-Dihydroxy-megastigman-5-ene 3-O-primeveroside (**12**): 1H NMR (DMSO- d_6 , 300 MHz) δ_H : 0.98 (6H, s, H-11, 12), 1.05 (3H, s, $J = 6.0$ Hz, H-10), 1.57 (3H, s, H-13), 1.30–1.38 (3H, m, H-2, H-8), 1.74 (1H, m, H-4ax), 1.89 (2H, m, H-7), 2.23 (1H, m, H-4 eq), 3.55 (2H, m, H-5b, H-9), 3.68 (1H, m, H-5''b), 3.89 (2H, m, H-6'b, H-3), 4.20 (1H, d, $J = 7.5$ Hz, H-1'), 4.24 (1H, d, $J = 7.8$ Hz, H-1'').

See Table 2 for ^{13}C NMR of compounds **5–12**.

3.3. Cytotoxic activity

To the best of our knowledge, this is the first report of the presence of sesquiterpenes in hawthorn. Many investigations have shown that the highly bioactive group of sesquiterpenes with a wide spectrum of biological activities, particularly antitumour and cytotoxic activities, make this group of exceptional interest (Cordell, 1976). So far it has been reported that the farnesane-type sesquiterpenoid generally show modest *in vitro* inhibition of the proliferation of the HeLa human cervical carcinoma cell line (CCL-2), with an IC₅₀ value of $4.5 \pm 0.2 \mu$ M (Liu, Zhou, Zhang, & Xuan, 2009).

Compounds **1–4** were evaluated for their *in vitro* cytotoxicity against human glioma (U87) cell lines by the MTT method (Hussain et al., 1993). Unfortunately, the tested compounds exhibited no significant cytotoxicity in the cell model system used (Table 3). It is hard to explain why compound **1** and **2** are inactive in human glioma (U87) cell lines. Maybe it is selective for cell lines or the *cis*-olefin methylene group (Z) makes their stereoconfiguration unable to bind to target proteins.

5. Conclusions

Phytochemical study of *C. pinnatifida* has resulted in four new sesquiterpenes (**1–4**), together with eight known ones (**5–12**). As far as we know, this is the first report of sesquiterpene isolated from this plant. Taking it into consideration that this plant is both a medicine and food material, our work is clearly important, revealing its chemical constituents.

In this study we have shown that four new compounds from hawthorn leaves exhibited no significant cytotoxicity in the cell model system used, based on the *in vitro* assay (U87). Further studies should also be carried out to reveal more hawthorn leaves ingredients and other pharmaceutical functions.

Acknowledgement

This work was supported by the Key Laboratory of Structure-Based Drug Design and Discovery (Shenyang Pharmaceutical University), Ministry of Education.

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.foodchem.2011.05.049](https://doi.org/10.1016/j.foodchem.2011.05.049).

References

- Agrawal, P. K. (1992). NMR spectroscopy in the structural elucidation of oligosaccharides and glycosides. *Phytochemistry*, 31(10), 3307–3330.
- Ammon, H. P. T., & Handel, M. (1981a). *Crataegus*, toxicology and pharmacology I. Toxicity. *Planta Medica*, 43(2), 105–120.
- Ammon, H. P. T., & Handel, M. (1981b). *Crataegus*, toxicology and pharmacology II. Pharmacodynamics and pharmacokinetics. *Planta Medica*, 43(2), 209–239.
- Ammon, H. P. T., & Handel, M. (1981c). *Crataegus*, toxicology and pharmacology III. Pharmacodynamics and pharmacokinetics. *Planta Medica*, 43(4), 313–322.
- Chang, J., & Case, R. (2005). Phenolic glycosides and ionone glycoside from the stem of *Sargentodoxa cuneata*. *Phytochemistry*, 66(23), 2752–2758.
- Chang, Q., Zuo, Z., Chow, M. S. S., & Ho, W. K. K. (2006). Effect of storage temperature on phenolics stability in hawthorn (*Crataegus pinnatifida* var. *major*) fruits and a hawthorn drink. *Food Chemistry*, 98(3), 426–430.
- Chen, J., & Song, S. J. (2005). Research progress in *Crataegus pinnatifida* Bge. *Research and Information on Traditional Chinese Medicine*, 7, 20.
- Cordell, G. A. (1976). Biosynthesis of sesquiterpenes. *Chemical Reviews*, 76(4), 425–460.
- Dauguet, J. C., Bert, M., Dolley, J., Bekaert, A., & Lewin, G. (1993). 8-Methoxykaempferol 3-neohesperidoside and other flavonoids from bee pollen of *Crataegus monogyna*. *Phytochemistry*, 33(6), 1503–1505.
- Frishman, W. H., Beravol, P., & Carosella, C. (2009). Alternative and complementary medicine for preventing and treating cardiovascular disease. *Disease-a-Month*, 55(3), 121–192.
- Frishman, W. H., Sinatra, S. T., & Moizuddin, M. (2004). The use of herbs for treating cardiovascular disease. *Seminars in Integrative Medicine*, 2(1), 23–35.
- Gao, P. Y., Li, L. Z., Peng, Y., Li, F. F., Niu, C., Huang, X. X., et al. (2010). Monoterpene and lignan glycosides in the leaves of *Crataegus pinnatifida*. *Biochemical Systematics and Ecology*, 38(5), 988–992.
- Hussain, R. F., Nouri, A. M. E., & Oliver, R. T. D. (1993). A new approach for measurement of cytotoxicity using colorimetric assay. *Journal of Immunological Methods*, 160(1), 89–96.
- Kishida, M., Fujii, M., Ida, Y., & Akita, H. (2005). Chemoenzymatic synthesis of naturally occurring (Z)-3-hexenyl 6-O-glycosyl-β-D-glucopyranosides. *Heterocycles*, 65(9), 2127–2137.
- Liu, S. S., Zhou, T., Zhang, S. W., & Xuan, L. J. (2009). Chemical constituents from *Clerodendrum bungei* and their cytotoxic activities. *Helvetica Chimica Acta*, 92(6), 1070–1079.
- Long, S. R., Carey, R. A., Crofoot, K. M., Proteau, P. J., & Filtz, T. M. (2006). Effect of hawthorn (*Crataegus oxycantha*) crude extract and chromatographic fractions on multiple activities in a cultured cardiomyocyte assay. *Phytomedicine*, 13(9/10), 643–650.
- Matsuda, N., Isawa, K., & Kikuchi, M. (1997). Megastigmane glycosides from *Lonicera gracilipes* var. *Glandulosa*. *Phytochemistry*, 45(4), 777–779.
- Meng, D. H., Wu, J., & Zhao, W. M. (2010). Glycosides from *Breynia fruticosa* and *Breynia rostrata*. *Phytochemistry*, 71(2–3), 325–331.
- Miyase, T., Ueno, A., Takizawa, N., Kobayashi, H., & Oguchi, H. (1988). Studies on the glycosides of *Epimedium grandiflorum* Morr. var. *thunbergianum* (Miq.) Nakai. III. *Chemical and Pharmaceutical Bulletin*, 36(7), 2475–2484.
- Nikolov, N., Seligmann, O., Wagner, H., Horowitz, R. M., & Gentili, B. (1982). New flavonoid-glycoside and *Crataegus monogyna* and *Crataegus pentagyna*. *Planta Medica*, 44(1), 50–53.
- Noiarsa, P., Yu, Q., Matsunami, K., Otsuka, H., Ruchirawat, S., & Kanchanapoom, T. (2007). (Z)-3-Hexenyl diglycosides from *Spermacoce laevis* Roxb. *Journal of Natural Medicines*, 61(4), 406–409.
- Otsuka, H. (1994). Linarionosides A–C and acyclic monoterpene diglycosides from *Linaria japonica*. *Phytochemistry*, 37(2), 461–465.
- Otsuka, H., & Tamaki, A. (2002). Platanionosides D–J: Megastigmane glycosides from the leaves of *Alangium platanifolium* (Sieb. et Zucc.) Harms var. *platanifolium* Sieb.. *Chemical and Pharmaceutical Bulletin*, 50(3), 390–394.
- Pittler, M. H., Schmidt, K., & Ernst, E. (2003). Hawthorn extract for treating chronic heart failure: Meta-analysis of randomized trials. *The American Journal of Medicine*, 114(8), 665–674.
- Tung, N. H., Ding, Y., Choi, E. M., Kiem, P. V., Minh, C. V., & Kim, Y. H. (2009). New anthracene glycosides from *Rhodomyrtus tomentosa* stimulate osteoblastic differentiation of MC3T3–E1 cells. *Archives of Pharmacol Research*, 32(4), 515–520.
- Yamamoto, M., Akita, T., Koyama, Y., Sueyoshi, E., Matsunami, K., Otsuka, H., et al. (2008). Euodionosides A–G: Megastigmane glucosides from leaves of *Euodia meliaeifolia*. *Phytochemistry*, 69(7), 1586–1596.
- Yao, M., Ritchie, H. E., & Brown-Woodman, P. D. (2008). A reproductive screening test of hawthorn. *Journal of Ethnopharmacology*, 118(1), 127–132.
- Zhang, P. C., & Xu, S. X. (2001). Flavonoid ketohexosefuranosides from the leaves of *Crataegus pinnatifida* Bge. Var. *major* N.E.Br.. *Phytochemistry*, 57(8), 1249–1253.
- Zhang, Z. S., Chang, Q., Zhu, M., Huang, Y., Ho, W. K. K., & Chen, Z. Y. (2001). Characterization of antioxidants present in hawthorn fruits. *The Journal of Nutritional Biochemistry*, 12(3), 144–152.
- Zhang, Z. S., Ho, W. K. K., Huang, Y., & Chen, Z. Y. (2002). Hypocholesterolemic activity of hawthorn fruit is mediated by regulation of cholesterol-7α-hydroxylase and acyl CoA: Cholesterol acyltransferase. *Food Research International*, 35(9), 885–891.